RotaTeq™

BIOLOGICAL5 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Bacterial InfectionsPneumococcal InfectionsPneumococcal VaccinesRotavirus InfectionsVirus Diseases

Phase 3

Rotavirus Efficacy and Safety Trial (REST)(V260-006)

CompletedNCT00090233

Merck Sharp & Dohme LLCRotavirus Infections

Start: 2001-01-31End: 2004-10-31Updated: 2015-10-05

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

CompletedNCT01337167

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-04-19End: 2013-05-09Updated: 2018-11-15

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

CompletedNCT01340937

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-05-10End: 2013-07-26Updated: 2018-11-15

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

CompletedNCT03620162

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-10-18End: 2020-12-14Updated: 2023-01-17

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

CompletedNCT03893448

Merck Sharp & Dohme LLCPneumococcal Infections, Pneumococcal Vaccines

Start: 2019-06-19End: 2021-05-24Updated: 2023-07-28

Related Papers

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

Expert Review of Vaccines2023-10-176 citations

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Vaccine2023-01-0141 citations

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

2022-12-1312 citations

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

UNC Libraries2019-08-18

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants.

2017-02-0116 citations

1112A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants

Open Forum Infectious Diseases2014-01-01

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5).

2010-06-118 citations